{"id":"amivantamab-sc","safety":{"commonSideEffects":[{"rate":"null","effect":"Interstitial lung disease"},{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297774","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to these receptors, amivantamab SC inhibits the signaling pathways that promote tumor growth and survival. This mechanism of action is thought to contribute to its therapeutic effects in patients with non-small cell lung cancer.","oneSentence":"Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:47.479Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation"},{"name":"Locally advanced or metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation"}]},"trialDetails":[{"nctId":"NCT07042295","phase":"PHASE2","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-23","conditions":"Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":418},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT04606381","phase":"PHASE1","title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-10","conditions":"Neoplasms","enrollment":158},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT07062354","phase":"PHASE2","title":"Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-02","conditions":"Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06116682","phase":"PHASE2","title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-19","conditions":"Lung Non-Small Cell Carcinoma","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-61186372"],"phase":"phase_2","status":"active","brandName":"Amivantamab SC","genericName":"Amivantamab SC","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors. Used for Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation, Locally advanced or metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}